Kornimate/medical-research-clean huggingface dataset:
rest study: left ventricular regression european study

Conditions: Aortic Valve Stenosis

Summary: the purpose of this study is to obtain data regarding the left ventricular mass (lvm) regression 6 months after the implant of an sjm epic™ and sjm epic™ supra valve by comparing lvm regression measured with magnetic resonance imaging (mri) to lvm regression measured with echocardiography (2-dimensional \[2d\] mandatory; 3-dimensional \[3d\] in sites where the technology is available).


Eligibility criteria:
inclusion criteria: * patient requires, for the first time, isolated aortic valve replacement due to aortic stenosis or mixed aortic stenosis disease etiology when aortic stenosis is predominant and aortic regurgitation is mild. * patient is of legal age in the host country. * patient (or legal guardian) has signed a study specific informed consent form exclusion criteria: * patient was previously operated on with any heart surgery including heart valve replacement or coronary artery bypass graft (cabg); or underwent any form of myocardial revascularization in the past (including stents), etc. * patient requires any concomitant heart surgery other than the isolated native aortic heart valve replacement and concomitant ascending aortic replacement (e.g not allowed are: multiple valve replacements or concomitant cabg, pacemaker insertions, or severe septal hypertrophy needing surgical excision, etc.) * patient has unstable angina * patient is in new york heart association functional class iv * patient has significant abnormality in wall motion * patient is affected by active endocarditis. * patient has a cardiac pacemaker or automatic implanted cardiac defibrillator * patient is affected by acute aortic dissection. * patient is in chronic and persistent atrial fibrillation * patient receives hemodialysis therapy * patient has a medical condition which contraindicates implantation of the sjm epic and epic™ supra porcine bioprosthetic heart valve (e.g. renal failure or abnormal calcium metabolism). * patient has aneurysmal clips or carotid artery vascular stents * patient has a neurostimulator * patient has an implanted or external drug infusion device (e.g. insulin pump) * patient has a bone growth/fusion stimulator * patient has a cochlear, otologic, or ear implant * patients with severe claustrophobia in which medical sedation is contraindicated or unable to resolve anxiety sufficiently * patients with ocular foreign body (e.g. metal shavings) * patient is pregnant or nursing

Keywords: aortic valve replacement
hemosonics - utmb cardiac surgery study

Conditions: Blood Loss, Surgical

Summary: this study will evaluate the performance of the quantra system comprised of the quantra hemostasis analyzer with the quantra qplus cartridge in patients undergoing cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device.

the quantra system is a fully integrated and automated in vitro diagnostic device which uses seer sonorheometry, and ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. the quantra qplus cartridge was developed to monitor hemostasis during major surgical procedures in adult patients. the cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding six parameters that depict the functional status of a patient's coagulation system. this single-center, prospective, observational study will evaluate the performance of the quantra system as compared to and comparable measures determined using the teg 5000.

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years * subject is scheduled for cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular access device. * subject is willing to participate, and he/she has signed a consent form. exclusion criteria: * subject is younger than 18 years * subject is unable to provide written informed consent * subject is incarcerated at the time of the study * subject is pregnant * subject is currently enrolled in a distinct study that might confound the results of the proposed study * subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Keywords: viscoelastic testing coagulation quantra hemostasis
thiamin deficiency in obese thai children

Conditions: Obesity; Child; Thiamine Deficiency

Summary: this study is aimed to assess the prevalence of thiamin deficiency in obese thai children.

this study is a cross-sectional study. the objectives of the study are to determine the prevalence of thiamin deficiency in obese thai children and to assess the associations of dietary factors and thiamin deficiency.

Eligibility criteria:
inclusion criteria: * obese : weight for height \> median + 3 standard deviations * simple obesity exclusion criteria: * pathological obesity * chronic diseases e.g. cerebral palsy, metabolic disease, etc. * diseases of red blood cells * on medication e.g. steroid, multivitamins, thiamine-containing vitamins, diuretic drugs * hemodialysis or peritoneal dialysis * bariatric surgery

Keywords: thiamine deficiency obese children thai
efficacy of platelet enriched plasma in preventing surgery for patients with chronic tympanic membrane perforation

Conditions: Tympanic Membrane Perforation

Summary: by doing this study, researchers hope to find out if platelet rich plasma (prp) can heal holes in the eardrum as an alternative to surgery.


Eligibility criteria:
inclusion criteria: * patients who meet criteria for tympanoplasty procedure * willing to comply with the protocol and attend all study visits * able to provide written informed consent exclusion criteria: * patients who have previously undergone middle ear or lateral skull base surgery * patients who would not qualify for a tympanoplasty * any type of platelet disorder, cancer, or ongoing systemic infection * any type of hemodynamic instability, septicemia, infection, tobacco use, any use of steroids to the ear drums * type i diabetes or other autoimmune pathology

Keywords: platelet rich plasma tm perforations hearing loss hole in the eardrum
quadratus lumborum plain block versus fascia iliac block

Conditions: Post Operative Pain

Summary: evaluation the efficacy of quadratus lumborum plain block versus fascia iliac block for postoperative pain after hip surgery


Eligibility criteria:
inclusion criteria: * 18-70 years * fracture hip exclusion criteria: * patients refuse * mental problem patient with any coagulation deficiency or bleeding problems patient with allergy to investigated medications,

Keywords: qlb fascia iliac block hip surgery
lower esophageal sphincter (les) stimulation in patients with ineffective esophageal motility

Conditions: Quality of Life; Dysphagia; Electrical Stimulation of the Lower Esophageal Sphincter; Gastro Esophageal Reflux

Summary: the aim of this study is to evaluate gastroesophageal reflux disease - health related quality of life (gerd-hrql) after electrical stimulation of the lower esophageal sphincter (les) in patients with gastroesophageal reflux disease (gerd) and esophageal dysmotility.

background the growing burden of gastroesophageal reflux disease (gerd) still impacts healthcare costs intensively. although the treatment with proton pump inhibitor (ppi) is effective in many cases, surgical treatment remains relevant due to a large amount of ppi refractory gerd. laparoscopic fundoplication (lf) is considered as standard procedure, but this type of surgery is linked to side effects as dysphagia, gas bloating and inability to belch. especially patients with ineffective esophageal motility (iem) are prone to postoperative dysphagia after lf. lower esophageal sphincter electrical stimulation (les-est) was introduced as an alternative technique to avoid side effects of lf. rodriquez et al. have bee demonstrated that les-est significantly raises the les pressure and improved gerd symptoms such as heartburn and regurgitation. the advantage of this procedure is that the anatomy of the esophageal-gastric junction is not altered dramatically. notably, patients with severely disordered esophageal peristalsis will benefit from this low-risk profile. after successful implementation of this technique at the medical university of vienna (ek 1149/2014), a prospective evaluation of data with the well established gastroesophageal reflux disease - health-related quality of life is next. patients with esophageal motility disorder, who undergo les-est, will be investigated towards side effects such as gas-bloating, inability to belch, flatulence and dysphagia.

Eligibility criteria:
inclusion criteria: * subject is indicated for les stimulation and plans to undergo antireflux surgery. * subject is meeting the criteria of iem (chicago classification v3.0) * subject provides signed informed consent exclusion criteria: * subject is within a vulnerable population or is unable to understand the informed consent. * subject is unwilling to attend follow-up visits.
a real-world study on hypertrophic cardiomyopathy in chinese population

Conditions: Hypertrophic Cardiomyopathy (HCM)

Summary: this study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the chinese population with hypertrophic cardiomyopathy (hcm) in real-world settings. the objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.


Eligibility criteria:
inclusion criteria: 1. willing and able to provide written informed consent (icf) and any required privacy authorization before the start of the study. 2. aged ≥18 years at the time of signing the written informed consent. 3. diagnosed with hypertrophic cardiomyopathy (hcm) according to the 2023 guideline for diagnosis and treatment of patients with hypertrophic cardiomyopathy, meeting the following criteria: 1. left ventricular wall thickness ≥15 mm in any segment at end-diastole, as assessed by echocardiography or cardiac magnetic resonance imaging (mri). 2. left ventricular wall thickness ≥13 mm in individuals with a positive pathogenic gene test or those identified as members of a genetically affected family. 3. exclusion of other cardiovascular diseases or systemic/metabolic diseases causing ventricular wall thickening. exclusion criteria: 1. uncontrolled primary hypertension. 2. moderate or severe aortic valve stenosis and/or primary mitral valve disease with severe mitral regurgitation. 3. confirmed infiltrative or storage diseases with a phenotype resembling hypertrophic cardiomyopathy (e.g., fabry disease, amyloidosis). 4. expected life expectancy \<1 years. 5. severe infections, liver failure, renal failure, or other life-threatening conditions.

Keywords: hypertrophic cardiomyopathy real-world study
urokinase like plasminogen activator levels in patients undergoing bronchoscopy

Conditions: Hemoptysis

Summary: some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. the etiology of this remains uncertain. the investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. the investigators plan to measure these factors prior to and after bronchoscopy.

this is a prospective observational study looking at some coagulation factors in individuals with lung cancer. we are looking at bal and plasma. we would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

Eligibility criteria:
inclusion criteria: * any patient scheduled to undergo bronchoscopy exclusion criteria: * patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000 * patients not scheduled to undergo bronchoalveolar lavage (bal)

Keywords: hemoptysis
telehealth for emergency-community continuity of care connectivity via home-telemonitoring

Conditions: Heart Failure

Summary: modern technology like computers, smartphones and the internet enable patients to measure certain health indicators, like blood pressure and body weight, from the comfort of their own homes. this information can also be shared electronically with doctors and other healthcare providers to monitor remotely. this is called home health monitoring. in tec4home, we are developing a home monitoring solution for patients with heart failure to support their care and recovery at home after a visit to the emergency department. we hope to show that this solution decreases revisits to the emergency department and increases quality of life for patients.


Eligibility criteria:
inclusion criteria: patient participants: * have one or more typical symptoms of heart failure (i.e. dyspnoea at rest or minimal exertion (includes orthopnoea, reduced exercise tolerance)) and * have one or more typical signs of heart failure (i.e. elevated jugular venous pressure, pulmonary crepitations, pleural effusions, peripheral oedema) and * have one or more objective measures of heart failure: radiological congestion. * elevated bnp ≥ 400 pg/ml or nt-probnp ≥ 1000 pg/ml. * reduced left ventricular ejection fraction \<40% (or \<45%) in previous 12 months. diastolic dysfunction including tissue doppler e/e' ratio \> 15 in previous 12 months. * pulmonary capillary wedge pressure \>20 mmhg. * diuretic therapy. the additional value of diuretic therapy (iv or oral) is debatable, as presumably unlikely (or unsafe) that patient with genuine hf will be discharged without diuretic. clinician participants: to be eligible to participate, clinician participants (i.e. ed physicians, family physicians and monitoring nurse(s)) must have referred or have a patient enrolled in the tec4home monitoring service. exclusion criteria: patient participants: * physical barriers e.g. unable to stand on scales. * cognitive impairment (e.g. mmse \<20), unless suitable caregiver support. * language (must be able to read and understand english), unless suitable caregiver support. * documented history of current and active substance misuse (within 3 months). * lack digital connectivity or landline phone connection. * no regular care provider e.g. gp, or at least regular walk-in clinic. * existing intensive system of care: lvad, transplant, dialysis. * anticipated improvement due to revascularization (pci/cabg) or valve intervention during index hospitalization. * anticipated survival \<90 days. active palliative care, less-than level iii care, disseminated malignancy. clinician participants: clinicians who do not have patients enrolled in the tec4home service or who themselves are not involved in the implementation or operation of the tec4home monitoring service will not be eligible to participate.
selective block of the axillary nerve in postoperative pain management

Conditions: Pain, Postoperative

Summary: in this study the investigators wish to compare the effect of a selective axillary nerve block to placebo in patients undergoing arthroscopic shoulder surgery. it is the investigators hypothesis that the amount of morphine consumption in the first 4 hours postoperatively in the intervention group will be significant lower than in the placebo group.


Eligibility criteria:
inclusion criteria: * subjects undergoing arthroscopic shoulder surgery * age between 18 and 80 years * asa 1-3 * bmi between 18 and 35 kg/m2 * subjects which have given their written informed consent exclusion criteria: * subjects unable to cooperate to the investigation * subjects not understanding or speaking danish * subjects allergic to intervention drugs * daily use of strong analgesics (morphine, oxycontine, ketogan) * alcohol or medicine misuse * failure of nerve block
severe hypoglycemia in pregnant women with type 1 diabetes

Conditions: Pregnancy; Diabetes

Summary: background: the risk of stillbirth and preterm delivery is three times increased among pregnant women with type 1 diabetes compared with healthy pregnant women. normal blood glucose levels are mandatory in order to prevent these complications. severe hypoglycemia (requiring assistance from another person) is the decisive limiting factor for obtaining near-normal blood glucose regulation in pregnant women with type 1 diabetes. severe hypoglycemia occurs in about one third of pregnancies complicated with type 1 diabetes and can result in unconsciousness, traffic accidents and deaths. aim: to test the following hypotheses: 1. severe hypoglycemia is frequent in pregnancy complicated by type 1 diabetes with the highest incidence in gestational weeks 8-16 and the lowest incidence in gestational weeks 28-34 2. predictors for severe hypoglycemia during pregnancy complicated with type 1 diabetes can be identified at the first pregnancy visit 3. possible pathophysiological mechanisms include changes in the growth hormone system and in the renin-angiotensin-system during pregnancy methodology: one hundred and eight pregnant women with type 1 diabetes are consecutively and prospectively included. in connection with the clinical control at the first pregnancy visit at week 9 and in gestational weeks 14, 22, 28, 34 and one day postpartum the following tests are carried out: the patients are asked to answer a validated questionnaire about mild and severe hypoglycemia and hypoglycemia-associated factors such as blood glucose level during hypoglycemia, the degree of awareness, pregnancy-associated nausea and vomiting, insulin type and dose etc. other medication, exercise habits, coffee- and alcohol intake, smoking and social status will be recorded. in case of severe hypoglycemia a structured interview concerning the episode will be performed within 24 hours. blood glucose, hba1c, the degree of insulin resistance and the levels of igf1, placenta growth hormone and of the renin-angiotensin-system will be monitored.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * pregnancy before gestational week 14 exclusion criteria: * other diseases that might influence the risk of severe hypoglycemia
long-term evaluation of single-piece acrysof iol implantation on development of posterior capsule opacification

Conditions: Posterior Capsule Opacification After Phacoemulsification and IOL Implantation

Summary: although contemporary cataract surgery has made tremendous strides in technological advancement, posterior capsular opacification (pco) is still the most frequent long-term complication leading to decreased visual functions and thereby dissatisfying results. a great deal of effort has been made to develop new ways to prevent the formation of pco. a key factor, widely discussed in literature, is the material and design of the intraocular lense (iol) edge that can lead to pco prevention. it is still not clear whether the sharp-edged iol produces less pco because of its optic geometry alone or whether the biomaterial contributes to the inhibition of pco. with the clinical introduction of the single-piece acrylic hydrophobic iols with some optic and haptic design differences compared with three-piece acrylic hydrophobic iols, it has become possible to determine the influence of iol material and design on pco prevention. it is well established that the development of pco is a dynamic process and that a longer follow-up time is correlated with a higher degree of pco. so far, there have been prospective clinical studies on the clinical results of single and three-piece acrylic hydrophobic foldable iols. however, the question as to as to whether the pco further increases or becomes stable or regresses on a long-term basis has not yet been answered. since there is paucity of available literature that prospectively evaluates the development of pco with the implantation of the single-piece sn60at hydrophobic acrylic iol on a long-term basis, the investigators decided to observe the degree of development of pco at 5 years after cataract surgery.


Eligibility criteria:
inclusion criteria: * patients with uncomplicated age-related cataract who were otherwise healthy exclusion criteria: * a history of diabetes mellitus (dm), * patients with glaucoma, * high myopia (axial length \> 27.0 mm), * pseudoexfoliation, * traumatic cataract, * subluxated cataract, * previous ocular surgeries, and * allergy to dilating drops.
cognitive behavioral therapy for health anxiety: internet treatment versus face-to-face therapy

Conditions: Severe Health Anxiety; Somatic Symptom Disorder; Illness Anxiety Disorder

Summary: background severe health anxiety is a highly distressing, often debilitating, psychological problem. since the release of the diagnostic and statistical manual of mental disorders 5 (dsm-5) its clinical manifestations are increasingly often referred to as somatic symptom disorder (ssd) or illness anxiety disorder (iad). despite often being overlooked in routine care, several treatments for severe health anxiety have shown great promise, the most well-established being cognitive behavioral therapy (cbt). traditionally, cbt - like most other psychotherapies - has typically been delivered face-to-face. that is, the patient physically meeting with the therapist once a week for the whole of the treatment. internet-delivered cbt does not rest on this requirement, but has nevertheless been shown to be efficacious for severe health anxiety (see for example nct01673035). aim of the study the present study aims to compare the effects of internet-delivered cbt and cbt face-to-face for severe health anxiety in a randomized controlled trial. a non-inferiority criterion is applied to determine if internet-delivered cbt is at least as efficacious as its well-established predecessor.


Eligibility criteria:
inclusion criteria: * a primary diagnosis of severe health anxiety (somatic symptom disorder or illness anxiety disorder) according to the diagnostic and statistical manual of mental disorders 5 (dsm-5) * registered citizen of stockholm county * at least 18 years old exclusion criteria: * other primary axis-i disorder * substance abuse or addiction during the last 6 months * current or previous episode of psychosis or bipolar disorder * severe major depressive disorder * suicide risk * personality disorder making the treatment procedure very difficult * non-stable psychiatric pharmacotherapy (dosage changed during the last 2 months) and the drug is likely to affect outcome measures * ongoing concurrent psychological treatment for severe health anxiety * having received previous high quality cognitive therapy or cognitive behavioural therapy during the recent year * ongoing serious somatic disorder, precluding cbt

Keywords: severe health anxiety somatic symptom disorder illness anxiety disorder cognitive behavioral therapy internet exposure
fmri based eeg neurofeedback as a method of enhancing emotional resilience among soldiers

Conditions: Stress; Depression

Summary: eeg protocols exist for reducing stress and improve ptsd symptoms (a/t eeg protocols, peniston, 1993, hammond, 2005) however; our innovative eeg-nf lmi approach intends to be more amygdala/stress specific and therefore more efficient. three groups of soldiers, while in operational activity will go through 24 sessions of 3 different methods of eeg-nf; our newly developed nf via mli, a standard procedure for nf via a/t and a placebo nf. difference between the groups in regard to their emotion regulation capability will be tested by fmri with regard to amygdala activation following eeg-nf lmi as well as two stress challenge tests.


Eligibility criteria:
inclusion criteria: * soldiers in preliminary combat training exclusion criteria: * known mental disorders or neuro-pathology

Keywords: stress and depression related symptoms